A phase 1 clinical study to assess the tolerability and steady state pharmacokinetics of MR-201 in healthy volunteers
Latest Information Update: 28 Nov 2022
At a glance
- Drugs MR-201 (Primary)
- Indications Emotional lability
- Focus Adverse reactions
Most Recent Events
- 28 Nov 2022 New trial record
- 21 Nov 2022 According to a Shinkei Therapeutics media release, the company is filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) of MR-201,